PDA

View Full Version : Articles of Interest

Pages : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 [17] 18
  1. No Pain, No Gain: A Fallacy So Far
  2. Outcomes of children exposed in utero to chemotherapy for breast cancer
  3. Would have been nice to know (left-side radiation)
  4. New concepts in breast cancer genomics and genetics
  5. Article in The Stranger about a Year with HER2+ BC
  6. Markers for the identification of late breast cancer recurrence
  7. Multigene prognostic tests in breast cancer: past, present, future
  8. Immune Function Genes Strongly Linked to Outcome of Trastuzumab Trial
  9. Using the exposome to predict BC risk
  10. Immunotherapy actually works
  11. Blood pressure medication and cancer patient
  12. Two New Genes.
  13. Study reveals effective tx for chemobrain
  14. Encouraging News
  15. From the NEJM: Loss of Fingerprints
  16. Long-term hazard of recurrence in HER2+ bc patients untreated with anti-Her2 therapy
  17. Quantification of HER family receptors in breast cancer
  18. From the NEJM: Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
  19. Also NEJM: The FDA and Genomic Tests — Getting Regulation Right
  20. Top 10 Reasons Against Routine Genomic Profiling of Tumors in Patient Care
  21. 1960s DDT Exposure Tied to Breast Cancer Risk 50 Years Later
  22. Very Interesting Implications for Pathology Results
  23. Intimacy Issues after Cancer Tx Not Discussed
  24. Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients
  25. Study-Neoadjuvant & PCR
  26. Immune system consequences of chemotherapy for bc
  27. UK Trial shows promising results for early lapatinib + herceptin
  28. Learning From the Lazarus Effect
  29. Study: Cancer center ads are costly, manipulative
  30. Basis for some Herceptin related heart SE's
  31. Breast Microbiome May Play a Role in Breast Cancer
  32. Accurate Predictors of Response to Endocrine Therapy
  33. Glucose and the development of bc
  34. How Breast Cancer Can Spread Before a Tumor Develops
  35. Familial cancer
  36. A educational video about one future of individualize immunotherapy
  37. current-standards-and-new-tratment-insights-in-her2-driven-metastatic-breast-disease
  38. cancer-researchers-worry-about-potential-downsides-of-immunotherapy
  39. how ironic
  40. Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer
  41. Onco test
  42. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
  43. Extended Adjuvant Aromatase Inhibition After Sequential Endocrine Therapy
  44. Her2 is not a cancer subtype, but a Pan Cancer Event
  45. If you ever develop heart failure, mention treatment
  46. Not all false positives from imaging are the same
  47. New Lymphadema tx
  48. Tumor Organoids Predict How Well Patients Respond to Cancer Drugs
  49. A study of how bc metastasizes
  50. Less Herceptin?
  51. Immunotherapy for MBC
  52. Some potential new drugs.
  53. Optimizing HER2-Targeted Therapy
  54. Emerging Treatments for HER2+ and Mutant Breast Cancer
  55. We can now customize cancer treatments, tumor by tumor
  56. Organic Foods for Cancer Prevention—Worth the Investment?
  57. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cel
  58. self-reported diet during treatment and chemotherapy-induced peripheral neuropathy
  59. Anti-tumor DaRT could point the way to new arsenal in battle against cancer
  60. New treatment for Alzheimer’s & potential uses for BC
  61. MacroGenics’ margetuximab beats Herceptin in phase 3
  62. HER2-Positive Breast Cancer and Resistance: What Next?
  63. Immune recognition of somatic mutations leading to complete durable regression in met
  64. Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce
  65. Cancer Patients Are Getting Robotic Surgery. There’s No Evidence It’s Better.
  66. A Clever New Strategy for Treating Cancer, Thanks to Darwin
  67. Why It Can Take So Long to Get Cancer Drugs
  68. VACCINE STUDY FOR HER2-POSITIVE BREAST CANCER MOVES FORWARD Volume 8, Issue 1, March
  69. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
  70. Breast Cancer Epidemiology and Prevention
  71. Cryotherapy for neuropathy.
  72. MacroGenics Announces Positive Results from Phase 3 SOPHIA of Margetuximab
  73. Specially created animal 'cancer avatars' could personalise treatments
  74. Amplification v.s Mutation
  75. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
  76. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
  77. Combination of Natural Agent with Synthetic Drug for the Breast Cancer Therapy
  78. Immunotherapy for HER2-positive breast cancer: recent advances and combination therap
  79. Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells
  80. Redrawing the Lines: The Next Generation ofTreatment in Metastatic Breast Cancer
  81. Chemotherapy principles of managing stage IV breast cancer in the United States
  82. Novel Agents May Challenge Standard Therapy in Advanced HER2+ Breast Cancer
  83. Neratinib versus Tucatinib
  84. Biomarkers for Immunotherapy: Current Developments andChallenges
  85. The Promise and Price of Cellular Therapies
  86. Targeted Agent and Profiling Utilization Registry (TAPUR)
  87. Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do
  88. metronomic eribulin
  89. Manage Diarrhea in Patients Receiving Nerlynx® (Neratinib)
  90. High fruit and vegetable consumption may reduce risk of breast cancer, especially agg
  91. Patients Liable to Be Misclassified Under New HER2 Gene Testing Guidelines, Expert Sa
  92. Association between HER2 positivity by HER2/CEP17 ratio
  93. The Fasting Cure Is No Fad
  94. Radical New Approach to Cancer Drug Use
  95. Why mouse models fail.
  96. Abscopal effect of radiotherapy
  97. Broccoli Is Dying. Corn Is Toxic. Long Live Microbiomes!
  98. Multiple modes of action of eribulin mesylate: Emerging data and clinical implication
  99. Mindfulness‐based cancer recovery and supportive‐expressive therapy maintain telomere
  100. Blood Test May Be Able To Predict Breast Cancer Relapse
  101. Stress and cancer metastasis
  102. A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-target
  103. Palbociclib and Letrozole and zearalenone and genistein
  104. CRISPR Approach To Fighting Cancer Called 'Promising' In 1st Safety Test
  105. Behind the Scenes of a Radical New Cancer "Cure"
  106. Complementary therapies can do more harm than good when breast cancer becomes visible
  107. Using Essential Oils for Aromatherapy
  108. Nutrient-wide association study of 92 foods and nutrients and breast cancer risk
  109. Molecular imaging to identify patients with benefit...endocrine treatment combined...
  110. Monitoring Tumor-Specific Mutations in Early-Stage Breast Cancer With ctDNA
  111. Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer
  112. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Re
  113. Combating subclonal evolution of resistant cancer phenotypes
  114. Is anyone familiar with using Noscapine for breast cancer treatment?
  115. Discovering the anticancer potential of non-oncology drugs by systematic viability pr
  116. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
  117. T-DM1–Associated Cardiotoxicity in Advanced HER2-Positive Breast Cancer
  118. Molecular profiling for precision cancer therapies
  119. Over come resistance to Neratinib with Affinitor.
  120. Psilocybin produces substantial and sustained decreases in depression and anxiety in
  121. Efficacy and Safety of Nab-Paclitaxel Compared With Solvent-Based Taxanes for Metasta
  122. Personalized Detection of Circulating Tumor DNAAntedates Breast Cancer Metastatic Rec
  123. A few Covid-19 and cancer articles
  124. In case you are making a mask.
  125. A few words about N95 respirator
  126. Perhaps something we can do in case we can't get treatment for covid-19.
  127. Vision problems due to anastrozole, bisphosphonate, or ???
  128. Discordance in ER/PR/Her2 ; Imaging to detect Hormone Receptor
  129. Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets
  130. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the P
  131. Treatment After Progression on CDK 4/6i in mBC
  132. Tucatinib aka ONT-380
  133. A couple of articles on current immunotherapy for her2 positive BC
  134. 6/2020:American Cancer Society Guideline for Diet and Physical Activity for cancer pr
  135. Cardiac monitoring in HER2-positive patients
  136. Hopefully this will be another weapon for us in the fight.
  137. Risk of early progression according to circulating ESR1 mutation...
  138. Leveraging CDK4/6 Inhibitors in Earlier Settings to Boost Outcomes in HR+ Breast Canc
  139. Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach
  140. Six distinct "types" of COVID-19 identified
  141. Combination Strategies ...Immunotherapy
  142. CDK4/6 inhibitors: The mechanism of action may not be as simple as once thought
  143. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inh
  144. Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors...
  145. “…evaluating palbociclib (CDK4/6) treatment outcome …”
  146. Circulating tumour DNA analysis to direct therapy in advanced breast cancer
  147. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profilin
  148. First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor Positive Ear
  149. This scientist made a Google Doc to educate the public about airborne coronavirus tra
  150. Breast cancer and covid
  151. Novel targeted therapies for metastatic breast cancer
  152. Clinical implications of prospectivegenomic profiling of metastatic breastcancer pati
  153. Heart health monitor: LVEF vs GLS
  154. Letter to a friend who was recently diagnosed with BC.
  155. Psilocybin produces substantial and sustained decreases in depression and anxiety in
  156. Genomic alterations in breast cancer: level ofevidence for actionability
  157. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer ...
  158. Complementary and integrative medicine for breast cancer patients - Evidence based pr
  159. The FDA has approved margetuximab-cmkb
  160. Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatmen
  161. Covid vaccines and cancer patients
  162. Cytotoxic T-cells mediate exercise-induced reductions in tumor growth
  163. Off topic:caring for healthcare professionals
  164. Androgens show new compelling evidence of anti-tumor activity
  165. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tum
  166. Targeting a neoantigen derived from a common TP53 mutation
  167. CDK 4/6 Inhibitors Are Associated With a High Incidence of Thrombotic Events in Breas
  168. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestra
  169. Tumor tissue- versus plasma-based genotyping for selection of matched therapy
  170. Hyperprogression in Patients With Cancer Receiving Immune Checkpoint Inhibitors
  171. weight-based IV dosing of trastuzumab vs SC fixed-dose
  172. Wire-Free Localization Technology for Breast Cancer Surgery
  173. Phenotypic changes of HER2-positive breast cancerduring and after dual HER2 blockade
  174. Treatment strategies for breast cancer brain metastases
  175. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Ad
  176. efficacy data about covid vaccine for high risk populations.
  177. Implementation of Precision Oncology for Patients withMetastatic Breast Cancer in an
  178. Perlmutter Cancer Center Researchers Find Breast Cancer Treatments Do Not Increase Ri
  179. Current and Future Management of HER2-Positive Metastatic Breast Cancer
  180. The emerging role of CDK4/6i in HER2-positive breast cancer
  181. CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast canc
  182. Advocating for Patients
  183. SYD985 /trastuzumab duocarmazine
  184. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-posi
  185. Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Pa
  186. Expert Discussion: HER2-Positive Breast Cancer
  187. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase
  188. Assessing Biomarkers in Metastatic Breast Cancer
  189. BioNTech mRNA Cancer Treatment Moved To Human Trials After Huge Success In Mice
  190. New cancer treatment may reawaken the immune system
  191. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy
  192. Elacestrant Shines in EMERALD Trial
  193. Aiming at a Tailored Cure for ERBB2 Positive Metastatic Breast Cancer:A Review
  194. covid infection and cancer patients ...
  195. Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibiti
  196. The Exciting New Field of HER2-Low Breast Cancer Treatment
  197. Current and future landscape of targeted therapy in HER2-positive advanced breastcanc
  198. NIH study advances personalized immunotherapy for metastatic breast cancer
  199. Treatment Switch After ESR1 Mutation Detected Shows Benefit
  200. Enhertu tightens its stranglehold
  201. IL-6 Is Biomarker for Distant Recurrence of Stage II/III Breast Cancer
  202. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective
  203. Emerging new therapeutic antibody derivatives for cancer treatment
  204. Assessment of a cancer genomic profile test for patients with metastatic breast cance
  205. Enhertu additional analyses ...metastatic breast cancer
  206. BC vaccine from your own tumor
  207. Exercise Recommendation for People With Bone Metastases
  208. A couple of informative articles on management of ER+ MBC
  209. Use of real-world data ...circulating tumor DNA (cfDNA) in identifying resistance
  210. Optimal timing and interval of imaging for metastatic breast cancer.
  211. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update
  212. Clinical implications of prospective genomic profiling of metastatic breast cancer pa
  213. Plant-Based and Ketogenic Diets As Diverging Paths to Address Cancer A Review
  214. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA t
  215. If you are looking for Evusheld (covid prophylactic)
  216. Enhertu and interstitial lung disease
  217. Amcenestrant in Endocrine-Resistant ER+/HER2− Advanced Breast Cancer
  218. Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus t
  219. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q
  220. Precision medicine improves outcomes in metastatic breast cancer
  221. Liquid biopsy–based biomarkers for the characterization of hormone receptor-positive
  222. Switch to Fulvestrant and Palbociclib vs No Switch in Advanced Breast Cancer With Ris
  223. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures
  224. Cancer Center Announces First Patient Has Received City of Hope’s Novel, Potentially
  225. Effects of weight-lifting or resistance exercise on breast cancer-related lymphedema:
  226. Application of HER2 peptide vaccines in patients with breast cancer: a systematic rev
  227. Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Surviv
  228. CRISPR cancer trial success paves the way for personalized treatments
  229. Warning: Popular Vitamin Supplement Causes Cancer Risk and Brain Metastasis
  230. Asco 2022 breast cancer research summary
  231. Promotion of hair growth by Rosmarinus officinalis leaf extract
  232. What Clinicians Want to Know: Addressing Current Questions and Controversies in the M
  233. Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastroz
  234. Paxlovid and other covid treatments.
  235. Datopotamab deruxtecan ... durable efficacy in patients with heavily pretreated
  236. Cancer vaccines are already a reality—but your doctor might ...
  237. How I treat HER2-low advanced breast cancer
  238. Free mobile application from the American Society of Clinical Oncology.
  239. Brain-Thought-Cancer-Sick
  240. Clinical utility of liquid biopsy in breast cancer: A systematic review
  241. Identifying the optimal therapeutics ... ER+ & Her2+
  242. Impact of Antibiotic Exposure ... Checkpoint Inhibitor Treatment
  243. Use of Alternative Medicine for Cancer and Its Impact on Survival
  244. ‘Chemo brain’ is real, but there are ways to ease it
  245. Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disord
  246. Genomic Assay Changes Minds on HER2+ Breast Cancer Treatment
  247. Upping levels of key nutrient maintains immune cell response to cancer
  248. Nature itself is the best physician
  249. Diclofenac for treatment of neuropathy from Capecitabine (Xeloda)
  250. long term comparing IV vs subcutaneous trastuzumab